AbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. Notably, when AbbVie announced the $8.7 billion acquisition of Cerevel back in December, the main focus of the deal was the experimental schizophrenia drug Emraclidine, part of a new class of medications that target the muscarinic receptor. Late last year, Bristol Myers Squibb also announced its entry into the field, buying Karuna Therapeutics for $14 billion. The Food and Drug Administration is reviewing Karuna’s drug for the treatment of schizophrenia.
Yahoo! Finance: CERE News
